Clinical characteristics and pathogen of patients with candidemia

Abstract

Abstract:

Objective To explore clinical features, pathogen distribution, antifungal resistance and prognosis of patients with candidiamia. Methods The clinical data of inpatients with candidemia from January 2011 to December 2018 in Zibo Central Hospital were retrospectively studied, and the risk factors, clinical features, species distribution, drug sensitivity and clinical outcomes were described and analyzed. Results The inpatients with candidemia were mainly from ICU (35.9%), and most of them were elderly patients (>60 years old, 75.7%). Candida albicans (40.8%) were the primary species, followed by C. tropicalis (20.4%), C. parapsilosis (20.4%), C. glabrata (10.7%) and C. krusei (3.9%). The separation rate of C. albicans showed the tendency of firstly increased and then decreased from 2011 to 2018, and non-albicans candidemia had risen in recent years. Azole resistance mainly arised in C. tropicalis and C. glabrata, and the sensitivity of C. albicans and C. parapsilosis to azole also declined. The 30-day crude mortality rate was 39.8%. Multivariate regression analysis revealed that agedness (OR=1.091, =0.001) and diabetes (OR=9.709, P=0.005) were independent risk factors, and targeted antifungal therapy (OR=0.142, P=0.008) could improve the prognosis of patients. Conclusion The incidence of candidemia can be reduced by treating basic diseases and reducing invasive operations in high-risk hospitalized patients, and the prognosis of patients can be improved by timely and targeted application of antifungal drugs.

Key words: candidemia, risk factors, antifungal susceptibility test, prognosis

CLC Number:

R519.3

ZHANG Wen, LUO Ying, GUO Cheng-jie, XU Ying-chun, XIAO Meng, LEI Cheng-bin, ZHAO Yan, BI Lei. Clinical characteristics and pathogen of patients with candidemia[J]. Chinese Journal of Mycology, 2020, 15(3): 154-160.

References

[1] Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals:analysis of 24,179 cases from a prospective nationwide surveillance study[J]. Clin Infect Dis, 2004, 39(3):309-317.
[2] Wang H, Xu YC, Hsueh PR. Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region[J]. Future Microbiol, 2016, 11:1461-1477.
[3] Colombo AL, Nucci M, Park BJ, et al. Epidemiology of candidemia in Brazil:a nationwide sentinel surveillance of candidemia in eleven medical centers[J]. J Clin Microbiol, 2006, 44(8):2816-2823.
[4] Ma CF, Li FQ, Shi LN, et al. Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China[J]. BMC Infect Dis, 2013, 13:337.
[5] ClSI. Performance Standards for Antifungal Susceptibility Testing of Yeasts. 1st ed[S]. CLSI supplement M60 Wayne, PA:Clinical and Laboratory Standards Institut. 2017.
[6] Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012[J]. J Clin Microbiol, 2012, 50(9):2846-2856.
[7] Tan BH, Chakrabarti A, Li RY, et al. Incidence and species distribution of candidaemia in Asia:a laboratory-based surveillance study[J]. Clin Microbiol Infect, 2015, 21(10):946-953.
[8] Guo F, Yang Y, Kang Y, et al. Invasive candidiasis in intensive care units in China:a multicentre prospective observational study[J]. J Antimicrob Chemother, 2013, 68(7):1660-1668.
[9] Wang H, Xiao M, Chen SC, et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study[J]. J Clin Microbiol, 2012, 50(12):3952-3959.
[10] 秦晓峰, 王英, 吴建华, 等. 院内深部念珠菌感染菌种分布和耐药性分析[J]. 中国真菌学杂志, 2016, 11(3):166-168.
[11] 屈玲, 李芳芹, 艾芳. 505株念珠菌感染特点及耐药性分析[J]. 国际检验医学杂志, 2011, 32(16):1830-1831.
[12] Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients[J]. Emerg Infect Dis, 2014, 20(11):1833-1840.
[13] Guinea J. Global trends in the distribution of Candida species causing candidemia[J]. Clin Microbiol Infect, 2014, 20(Suppl 6):5-10.
[14] Hirano R, Sakamoto Y, Kitazawa J, et al. Epidemiology, practice patterns, and prognostic factors for candidemia; and characteristics of fourteen patients with breakthrough Candida bloodstream infections:a single tertiary hospital experience in Japan[J]. Infect Drug Resist, 2018, 11:821-833.
[15] Barchiesi F, Orsetti E, Gesuita R, et al. Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014[J]. Infection, 2016, 44(2):205-213.
[16] Luzzati R, Cavinato S, Deiana ML, et al. Epidemiology and outcome of nosocomial candidemia in elderly patients admitted prevalently in medical wards[J]. Aging Clin Exp Res, 2015, 27(2):131-137.
[17] Antinori S, Milazzo L, Sollima S, et al. Candidemia and invasive candidiasis in adults:A narrative review[J]. Eur J Intern Med, 2016, 34:21-28.
[18] Hadley S, Lee WW, Ruthazer R, et al. Candidemia as a cause of septic shock and multiple organ failure in nonimmunocompromised patients[J]. Crit Care Med, 2002, 30(8):1808-1814.
[19] Kullberg BJ, Arendrup MC. Invasive candidiasis[J]. N Engl J Med, 2015, 373(15):1445-1456.
[20] Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis:2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 62(4):e1-50.
[21] Guo LN, Xiao M, Cao B, et al. Epidemiology and antifungal susceptibilities of yeast isolates causing invasive infections across urban Beijing, China[J]. Future Microbiol, 2017, 12:1075-1086.
[22] Arendrup MC. Update on antifungal resistance in Aspergillus and Candida[J]. Clin Microbiol Infect, 2014, 20(Suppl 6):42-48.
[23] Morace G, Perdoni F, Borghi E. Antifungal drug resistance in Candida species[J]. J Glob Antimicrob Resist, 2014, 2(4):254-259.
[24] Cuenca-Estrella M. Antifungal drug resistance mechanisms in pathogenic fungi:from bench to bedside[J]. Clin Microbiol Infect, 2014, 20(Suppl 6):54-59.